Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects
Organ Medicine · 2026-03 · 3 (1) · 27-53
DOI: 10.1002/orm2.70037 ↗At a glance
Journal article in Organ Medicine, published online on 2026-03-17. Written by Zhenyu Liu and 3 co-authors. Cited 3 times so far (Crossref); 159 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China.
Abstract (original language)
Atherosclerosis, a chronic inflammatory–metabolic disorder, remains a leading cause of cardiovascular morbidity worldwide. This review explores the emerging paradigm of nanomedicine‐based targeting of macrophage immunometabolic reprogramming as a potentially transformative strategy for atherosclerosis treatment. We emphasize innovative approaches such as stimulus–responsive nanocarriers (e.g., pH‐, reactive oxygen species‐, or enzyme‐activated systems) for spatiotemporal drug delivery and metabolic modulation within plaques, and nanoplatforms for delivering genetic regulators (e.g., small interfering RNA or microRNA) for precise manipulation of key metabolic targets, including 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase 3 (glycolysis) and ATP‐binding cassette A1 (cholesterol efflux). Despite promising preclinical outcomes, clinical translation faces substantial challenges, including optimizing nanocarrier biocompatibility, achieving subtype‐specific targeting amid macrophage heterogeneity, and resolving scalability and standardization issues. Future advancements will require interdisciplinary collaboration integrating immunometabolism, materials science, and artificial intelligence to develop next‐generation nanotherapeutics, coupled with robust clinical validation to facilitate their translation into personalized therapies for atherosclerosis.
Funding
- National Natural Science Foundation of China
Cite
APA
Liu, Z., Yang, W., Wang, N., & Wu, Y. (2026). Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects. Organ Medicine, 3(1), 27-53. https://doi.org/10.1002/orm2.70037
Vancouver
Liu Z, Yang W, Wang N, Wu Y. Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects. Organ Medicine. 2026;3(1):27-53. doi:10.1002/orm2.70037
BibTeX
@article{Liu2026,
author = {Liu, Zhenyu and Yang, Wenfan and Wang, Na and Wu, Ya},
title = {Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects},
journal = {Organ Medicine},
year = {2026},
volume = {3},
number = {1},
pages = {27--53},
doi = {10.1002/orm2.70037}
}
EUVIMED